glp-1/gip/gcg receptor agonist Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Novel Therapies for Cardiometabolic Disease:

By Michael S

2023 brought with it many medical advances, including the "skinny shot" for weight loss, known in its various formulations as the brand names Ozempic, Wegovy, Mounjaro and others

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month

Elon Musk wants to cut funding for scientific research, but the weight loss drugs he promoted also came from government funded basic science.

Tirzepatide displayed an unprecedented glucose and body weight lowering potential, presenting also with the ability to increase insulin sensitivity, reduce systolic blood pressure and inflammation and ameliorate dyslipidemia, particularly by reducing triglycerides levels